|
Re: At least RVX has a shorter trial timeline than ESPR
|
4
|
Resverlogix Corp.
|
May 05, 2016 08:01PM
|
|
Re: At least RVX has a shorter trial timeline than ESPR
|
5
|
Resverlogix Corp.
|
May 06, 2016 03:15PM
|
|
Re: At 1.33 we're over both the 20 and 50 DMAs....
|
3
|
Resverlogix Corp.
|
Jun 09, 2016 10:11AM
|
|
Re: AstraZeneca heart drug fails in key stroke trial .
|
2
|
Resverlogix Corp.
|
Mar 23, 2016 05:52PM
|
|
Re: ASN late breaker and CKD sub-study top-line
|
5
|
Resverlogix Corp.
|
Oct 11, 2019 11:23AM
|
|
Re: As we finish another brutal year as retail shareholders....
|
7
|
Resverlogix Corp.
|
Dec 30, 2021 10:26AM
|
|
Re: As we appear to have a flat tire down at the registry...you then read this from Fauci!
|
6
|
Resverlogix Corp.
|
May 07, 2021 01:23PM
|
|
Re: As Pfizer charges ahead....
|
5
|
Resverlogix Corp.
|
Sep 04, 2021 12:23PM
|
|
Re: As much as I think we're on the cusp......
|
1
|
Resverlogix Corp.
|
Sep 08, 2017 10:08AM
|
|
Re: Article
|
7
|
Resverlogix Corp.
|
May 31, 2022 12:54PM
|
|
Re: Article
|
1
|
Resverlogix Corp.
|
Mar 15, 2022 11:27AM
|
|
Re: Array and Zenith
|
4
|
Zenith Epigenetics
|
Jun 22, 2019 12:26PM
|
|
Re: Apropos AGM
|
4
|
Resverlogix Corp.
|
Jun 08, 2022 06:27PM
|
|
Re: Apropos AGM
|
6
|
Resverlogix Corp.
|
Jun 08, 2022 01:14PM
|
|
Re: Apropos AGM
|
6
|
Resverlogix Corp.
|
Jun 06, 2022 12:54PM
|
|
Re: Apropos AGM
|
4
|
Resverlogix Corp.
|
Jun 08, 2022 06:22PM
|
|
Re: Apabetalone’s Positive Impact on COVID-19 in Human Lung Cells Published in Biomedicines
|
4
|
Resverlogix Corp.
|
Apr 21, 2021 11:25AM
|
|
Re: Apabetalone treatment reduces SARS-CoV-2 infectivity and completely prevents cardiac damage in a cytokine-storm model
|
8
|
Resverlogix Corp.
|
Mar 03, 2021 10:31AM
|
|
Re: Apabetalone MOA diagram
|
2
|
Resverlogix Corp.
|
Sep 28, 2019 02:57PM
|
|
Re: Apabetalone MOA diagram
|
7
|
Resverlogix Corp.
|
Sep 29, 2019 12:30PM
|
